Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03868345 · ClinicalTrials.gov registry record
Speech Analysis in ALS Patients
A clinical trial, sponsored by Barrow Neurological Institute.
- Completed
- Registry status
- 26
- Enrollment target
NCT03868345: Completed study, sponsored by Barrow Neurological Institute.
NCT03868345 is a clinical trial that has completed, run by Barrow Neurological Institute. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03868345 has completed, sponsored by Barrow Neurological Institute.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year. Every three months, patients will undergo a series of cognitive and basic clinical outcomes tests. In addition, participants will take home a study-provided tablet on which they will complete weekly speech recording activities.
Primary Outcome
Speech recordings made at home via a tablet using the " SpeechAssess" app.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-02-18 |
| Est. Completion | 2021-04-30 |
What the finished NCT03868345 record still lists
NCT03868345 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03868345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03868345 about?
NCT03868345 is a clinical study titled "Speech Analysis in ALS Patients". The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year. Every three months, patients will undergo a series of cognitive and basic clinical outcomes tests. ...
What is the current status of trial NCT03868345?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2019-02-18. Estimated completion is 2021-04-30.
Who is sponsoring clinical trial NCT03868345?
This trial is sponsored by Barrow Neurological Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI